CÁNCER DE CABEZA Y CUELLO: UNA PERSPECTIVA HISTÓRICA

  • Juan Esteban García-Robledo Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali
Palabras clave: Cáncer de cabeza y cuello, Historia del cáncer, Inmunoterapia, terapia dirigida

Resumen

El cáncer de cabeza y cuello es una entidad cada vez más frecuente, caracterizada por relacionarse con desfiguración facial y generar en los pacientes que lo padecen, no sólo una alta tasa de morbilidad somática sino también psiquiátrica. La historia de este tipo de tumores data de algunos años antes de la era común (también conocida como antes de Cristo) y se extiende, con una evolución progresiva hasta nuestros días, con una aceleración mayor en las últimas 4 décadas. La historia nos muestra como el empirismo, el pensamiento crítico y la lógica de ensayo y error fueron fundamentales en los avances iniciales hacia el diagnóstico y tratamiento del cáncer de cabeza y cuello, en épocas en las que los conocimientos de biología fundamental no eran sino esbozos, y donde incluso algunas teorías espirituales servían como explicación.

Biografía del autor/a

Juan Esteban García-Robledo, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali
M.D. Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.

Citas

1. Chow LQM. Head and Neck Cancer. N Engl J Med 2020; 382:60–72.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
3. ACKERKNECHT EH. Historical notes on cancer. Med Hist. 1958;2:114–119.
4. Moodie RL. Tumors of the head among the pre-Columbian Peruvians. Ann Med Hist. 1926;8:394–412.
5. Bernal JE, Briceno I. Genetic and other diseases in the pottery of Tumaco-La Tolita culture in ColombiaEcuador. Clin Genet. 2006;70:188–191.
6. Bhikha R, Glynn J. The theory of humours revisited. Int J Dev Res. 2017;7:15029–15034.
7. Hajdu SI. A note from history: Landmarks in history of cancer, part 1. Cancer. 2011;117:1097–1102.
8. di Lonardo A, Nasi S, Pulciani S. Cancer: We should not forget the past. J. Cancer. 2015;6:29–39.
9. Lukong KE. Understanding breast cancer – The long and winding road. BBA Clin. 2017;7:64–77.
10. Natale G, Bocci G, Ribatti D. Scholars and scientists in the history of the lymphatic system. J. Anat. 2017;231:417–429.
11. Shedd DP. The Work of Henry T. Butlin, an Early Head and Neck Surgeon. Am J Surg. 1997;173:234–236.
12. Inchingolo F, Santacroce L, Ballini A, Topi S, Dipalma G, Haxhirexha K et al. Oral Cancer: A Historical Review. Int J Environ Res Public Health. 2020;17:3168.
13. McGurk M, Goodger NM. Head and neck cancer and its treatment: historical review. Br J Oral Maxillofac Surg . 2000;38:209–220.
14. Martin HE. The history of lingual cancer. Am J Surg. 1940;48:703–716.
15. Redmond DE. Tobacco and Cancer: The First Clinical Report, 1761. N Engl J Med. 1970;282:18–23.
16. von Soemmerring ST. De Morbis vasorum absorbentium corporis humani... Varrentrapp et Wenneri, 1795.
17. Pott P. The chirurgical works of Percivall Pott, F.R.S., surgeon to St. Bartholomew’s Hospital, a new edition, with his last corrections. 1808. Clin Orthop Relat Res. 2002;:4–10.
18. Marchetti P. Observationum medico-chirurgicarum rariorum sylloge. Cadorinis, 1737.
19. Louis A. Memoire physiologique et pathologique sur la langue. 1770.
20. Absolon KB, Rogers W, Aust JB. Some historical developments of the surgical therapy of tongue cancer from the seventeenth to the nineteenth century. Am J Surg. 1962;104:686–691.
21. Middeldorpf AT. Die Galvano caustik ein Beitrag zur operativen Medicin. Josef Max & Comp., 1854.
22. Maisoneuve M. Sur un cas d’extirpation presque totale de la langue au moyen de la cauterisation en flesches. J Compt Rend Acad Sc. 1863;57: 831.
23. Billroth T. Osteoplastiche Resectionen des Unterkiefers nach Eigener Methode. Arch Klin Chri . 1862;2:651–657.
24. Stell PM. History of surgery of the upper jaw. Tumours Up jaw Edinburgh Ed Churchill Livingstone 1993;:1–15.
25. Garcia M. IV. Observations on the human voice. Proc R Soc London 1856;:399–410.
26. Sir Morell Mackenzie (1837–1892). Nature. 1937;140:16.
27. Stevenson RS, Guthrie D. A history of oto-laryngology. E. & S. Livingstone, 1949.
28. Thomson SC. Cancer of the Larynx. Laryngoscope. 1921;31:522–527.
29. Thomson S. The history of cancer of the larynx. J Laryngol Otol . 1939;54:61–87.
30. Stell PM. The first laryngectomy. J Laryngol Otol . 1975;89:353–358.
31. Röntgen WC. Über eine neue Art von Strahlen. Sitzungsberichte der Physik.-Med. Gesellschaft zu Würzbg . 1895;137:132–141.
32. Dunn PM. Wilhelm Conrad Röentgen (1845-1923), the discovery of x rays and perinatal diagnosis. Arch. Dis. Child. Fetal Neonatal Ed. 2001;84(2):F138-9.
33. Radvanyi P, Villain J. La découverte de la radioactivité. Comptes Rendus Phys. 2017;18:544–550.
34. Paterson R, Parker HM. A Dosage System for Gamma Ray Therapy. Br J Radiol 1934;7:592–632.
35. Coutard H. Roentgentherapie des epitheliomas de la region amygdalienne, de l’hypopharynx et du larynx au cours des annees 1920 a 1926. Radiophys et radiothérapie . 1932;2:11–27.
36. Duane W. Methods of preparing and using radioactive substances in the treatment of malignant disease, and of estimating suitable dosages. Bost Med Surg J. 1917;177:787–799.
37. Dominici H. Du traitement des tumeurs malignes par le rayonnement ultrapénétrant du radium. Bull Cancer. 1908;1:124–156.
38. Butlin HT. The hunterian lecture on what operation can do for cancer of the tongue. Br Med J. 1898;1:541– 544.
39. Butlin HT. On the Early Diagnosis of Cancer of the Tongue, and on the Results of Operations in Such Cases. Br Med J. 1909;1:462–463.
40. Crile G. Excision of cancer of the head and neck: With special reference to the plan of dissection based on one hundred and thirty-two operations. J Am Med Assoc .1906;XLVII:1780–1786.
41. Watne AL. Treatment alternatives: Head and neck cancers. Cancer . 1984;54:2673–2681.
42. Hong WK, Bromer R. Chemotherapy in Head and Neck Cancer. N Engl J Med. 1983;308:75–79.
43. Levitt M, Mosher MB, DeConti RC, Farber LR, Skeel RT, Marsh JC et al. Improved therapeutic index of methotrexate with ‘leucovorin rescue’. Cancer Res. 1973;33:1729–1734.
44. Baker SR, Makuch RW, Wolf GT. Preoperative Cisplatin and Bleomycin Therapy in Head and Neck Squamous Carcinoma: Prognostic Factors for Tumor Response. Arch Otolaryngol . 1981;107:683–689.
45. Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report of intergroup study 0034. Int J Radiat Oncol Biol Phys . 1992;23:705–713.
46. Cognetti DM, Weber RS, Lai SY. Head and neck Cancer an evolving treatment paradigm. Cancer. 2008;113:1911–1932.
47. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–955.
48. Baujat B, Audry H, Bourhis J, Chan ATC, Onat H, Chua DTT et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56.
49. Krasinskas AM. EGFR Signaling in Colorectal Carcinoma. Patholog Res Int . 2011;2011:1–6.
50. Fernández-Trujillo L, Garcia-Robledo JE, ZúñigaRestrepo V, Sua LF. Clinical characteristics and PDL1 expression in primary lung squamous cell carcinoma: A case series. Respir Med Case Reports . 2020;30:101114.
51. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.
52. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359:1116–1127.
53. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarvala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77–85.
54. Vermorken JB, Trigo J, Hitt R, Koralewski P, DiazRubio E, Rolland F et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171– 2177.
55. Lawrence MS, Sougnez C, Lichtenstein L, Cibulskis K, Lander E, Gabriel SB et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582.
56. Gougis P, Bachelard CM, Kamal M, Gan HK, Borcoman E, Torossian N et al. Clinical development of molecular targeted therapy in head and neck squamous cell carcinoma. JNCI Cancer Spectr. 2019;3(4):pkz055
57. Beltran E, Garcia-Robledo JE, Rodríguez-Rojas LX, Rengifo M, Perez B, Pachajoa H et al. Clear cell renal carcinoma synchronous with dedifferentiated liposarcoma: a case report and review of the literature. J Med Case Rep. 2020;14(1):4.
58. Ghanizada M, Jakobsen KK, Grønhøj C, von Buchwald C. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review. Oral Oncol. 2019;90:67–73.
59. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G et al. Pembrolizumab alone or with chemotherapy vs. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet .2019;394:1915– 1928.
60. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–1867.
61. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ et al. Pembrolizumab vs. methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156–167.
62. Garcia-Robledo JE, Barrera MC, Tobón GJ. CRISPR/ Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases. Int Rev Immunol . 2020;39:11–20.
63. Birkeland A, Ludwig ML, Spector ME, Brenner JC. The potential for tumor suppressor gene therapy in head and neck cancer. Discov Med 2016;21:41.
64. Liu S, Chen P, Hu M, Tao Y, Chen L, Liu H et al. Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer. Cancer Gene Ther. 2013;20:375–378.
65. Yoo GH, Moon J, LeBlanc M, Lonardo F, Urba S, Kim H et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the southwest oncology group. Arch Otolaryngol - Head Neck Surg. 2009;135:869–874.
66. Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol . 2020;7:e816–e826.
67. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–2544.
68. Mei Z, Zhang K, Lam AKY, Huang J, Qiu F, Qiao B et al. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med.
69. Wang S, Zhu Z. Enhanced chimeric antigen receptor T-cell therapy: A novel approach for head and neck cancers. Oral Dis. 2019;25:355–356.
70. Papa S, Adami A, Metoudi M, Achkova D, van Schalkwyk M, Parente Pereira A et al. A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC). J Clin Oncol . 2018;36:3046– 3046.
Publicado
2021-04-20
Sección
Perspectiva del diagnóstico y Tratamiento del Cancer